Keryx Shouldn't Get 2nd Chance To Ax Stock Suit, Court Told
Investors in Keryx Biopharmaceuticals Inc. shot back Thursday at the company's attempt to reargue its motion to dismiss a proposed class action alleging the company misled investors to believe it had...To view the full article, register now.
Already a subscriber? Click here to view full article